|
Type of bDMARD
|
|
TNFi(mAb)/TNFi(R/P)
|
0.56 (0.35–0.87)
|
0.01
|
|
TNFi(mAb)/CTLA4-Ig
|
0.87 (0.48–1.57)
|
0.65
|
|
TNFi(mAb)/IL-6Ri
|
0.42 (0.28–0.63)
|
< 0.01
|
|
CTLA4-Ig/TNFi(R/P)
|
0.64 (0.33–1.24)
|
0.19
|
|
CTLA4-Ig/IL-6Ri
|
0.48 (0.25–0.91)
|
0.03
|
|
TNFi(R/P)/IL-6Ri
|
0.75 (0.46–1.25)
|
0.27
|
|
Age (years)
|
1.00 (0.99–1.01)
|
0.88
|
|
Sex, female/male
|
0.79 (0.53–1.20)
|
0.26
|
|
Disease duration, < 2 years/≥ 2 years
|
0.63 (0.45–0.88)
|
0.01
|
|
Disease duration (years)
|
1.03 (1.01–1.05)
|
< 0.01
|
|
Smoking status, current/previous or never
|
0.62 (0.27–1.21)
|
0.17
|
|
Anti-CCP antibody, positive/negative
|
1.47 (0.84–2.81)
|
0.19
|
|
Rheumatoid factor, positive/negative
|
1.39 (0.91–2.21)
|
0.13
|
|
bDMARD-naïve, naïve/switch
|
0.56 (0.40–0.79)
|
< 0.01
|
|
Reason for discontinuation, remission/other reason
|
0.36 (0.22–0.58)
|
< 0.01
|
|
Boolean remission at the time of discontinuation, achieved/not achieved
|
0.42 (0.29–0.60)
|
< 0.01
|
|
Remission maintenance period before discontinuation, > 6 months/≥ 6 months
|
0.33 (0.22–0.50)
|
< 0.01
|
|
Methotrexate usage at the time of discontinuation, yes/no
|
0.65 (0.45–0.96)
|
0.03
|
|
Methotrexate dosage at the time of discontinuation (mg/week)
|
0.95 (0.92–0.99)
|
0.02
|
|
Glucocorticoid usage at the time of discontinuation, yes/no
|
2.03 (1.46–2.82)
|
< 0.01
|
|
Glucocorticoid dosage at the time of discontinuation (mg/day)
|
1.01 (0.98–1.02)
|
0.56
|
